Artificial intelligence for dementia drug discovery and trials optimization

Doherty, Thomas, Yao, Zhi, Khleifat, Ahmad A.l., Tantiangco, Hanz, Tamburin, Stefano, Albertyn, Chris, Thakur, Lokendra, Llewellyn, David J., Oxtoby, Neil P., Lourida, Ilianna, Ranson, Janice M. and Duce, James A. 2023. Artificial intelligence for dementia drug discovery and trials optimization. Alzheimer's & Dementia. https://doi.org/10.1002/alz.13428

TitleArtificial intelligence for dementia drug discovery and trials optimization
TypeJournal article
AuthorsDoherty, Thomas, Yao, Zhi, Khleifat, Ahmad A.l., Tantiangco, Hanz, Tamburin, Stefano, Albertyn, Chris, Thakur, Lokendra, Llewellyn, David J., Oxtoby, Neil P., Lourida, Ilianna, Ranson, Janice M. and Duce, James A.
AbstractDrug discovery and clinical trial design for dementia have historically been challenging. In part these challenges have arisen from patient heterogeneity, length of disease course, and the tractability of a target for the brain. Applying big data analytics and machine learning tools for drug discovery and utilizing them to inform successful clinical trial design has the potential to accelerate progress. Opportunities arise at multiple stages in the therapy pipeline and the growing availability of large medical data sets opens possibilities for big data analyses to answer key questions in clinical and therapeutic challenges. However, before this goal is reached, several challenges need to be overcome and only a multi‐disciplinary approach can promote data‐driven decision‐making to its full potential. Herein we review the current state of machine learning applications to clinical trial design and drug discovery, while presenting opportunities and recommendations that can break down the barriers to implementation.
KeywordsPsychiatry and Mental health
Cellular and Molecular Neuroscience
Geriatrics and Gerontology
Neurology (clinical)
Developmental Neuroscience
Health Policy
Epidemiology
JournalAlzheimer's & Dementia
ISSN1552-5260
1552-5279
Year2023
PublisherWiley
Publisher's version
License
CC BY 4.0
File Access Level
Open (open metadata and files)
Digital Object Identifier (DOI)https://doi.org/10.1002/alz.13428
PubMed ID37587767
Publication dates
Published online16 Aug 2023
FunderNational Institute for Health Research
National Health and Medical Research Council
Licensehttp://creativecommons.org/licenses/by/4.0/

Related outputs

Understanding Cognitive Variability in Alzheimer’s Disease
Doherty, Thomas 2023. Understanding Cognitive Variability in Alzheimer’s Disease. PhD thesis University of Westminster Social Sciences https://doi.org/10.34737/w166v

Increasing the Cognitive Screening Efficiency of Global Phase III Trials in Early Alzheimer Disease: The Cognitive Task Force
Doherty, Thomas, Gee, Michelle, Maruff, Paul, Smith, Robert, Murphy, Jennifer, Marsh, Julie, Koschalka, Luke, Martinez, Mairelys, Irizarry, Michael and Albala, Bruce 2022. Increasing the Cognitive Screening Efficiency of Global Phase III Trials in Early Alzheimer Disease: The Cognitive Task Force. Alzheimer disease and associated disorders. 36 (3), pp. 185-191. https://doi.org/10.1097/WAD.0000000000000508

Permalink - https://westminsterresearch.westminster.ac.uk/item/w4wvz/artificial-intelligence-for-dementia-drug-discovery-and-trials-optimization


Share this

Usage statistics

45 total views
33 total downloads
These values cover views and downloads from WestminsterResearch and are for the period from September 2nd 2018, when this repository was created.